1 Lai, C.C., Shih, T.P., Ko, W.C., Tang, H.J., Hsueh, P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 55, 105924 (2020).
2 WHO. Director-General’s opening remarks at the media briefing on COVID-19—11 March. 2020. https://www. who.int/director-general/speeches/detail/who-directorgeneral-s-opening-remarks-at-the-media-briefing-oncovid-19---11-march-2020.
3 Zhang, J.J. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 75, 1730-1741. doi: 10.1111/all.14238 (2020).
4 Chiba, S. Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19. Wien Klin Wochenschr. 133, 292-297. doi: 10.1007/s00508-020-01780-0 (2021).
5 Wang, L. et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 80, 639-645. doi: 10.1016/j.jinf.2020.03.019 (2020).
6 Pelechas, E., Drossou, V., Voulgari, P.V., Drosos, A.A. Anti-rheumatic drugs for the fight against the novel coronavirus infection (SARS-CoV-2): what is the evidence? Mediterr J Rheumatol. 31(Suppl 2), 259-267. doi: 10.31138/mjr.31.3.259 (2020).
7 WHO Statement: Tobacco Use and COVID-19. Available online: https://www.who.int/news/item/11-05-2020-who-statement-tobacco-use-and-covid-19
8 Tattersfield, A.E., Knox, A.J., Britton, J.R., Hall, I.P. Asthma. Lancet. 360, 1313-22. doi: 10.1016/s0140-6736(02)11312-2 (2002).
9 Yamanaka, T. et al. Evaluation of twenty-two rapid antigen detection tests in the diagnosis of equine influenza caused by viruses of H3N8 subtype. Influenza Other Respir Viruses. 10, 127–33 (2016).
10 Ponsioen, B.P., Hop, W.C., Vermue, N.A., Dekhuijzen, P.N., Bohnen, A.M. Efficacy of fluticasone on cough: a randomised controlled trial. Eur Respir J. 25, 147-52. doi: 10.1183/09031936.04.00053604 (2005).
11 Arcavi, L., Benowitz, N.L. Cigarette smoking and infection. Arch Intern Med. 164, 2206-16. doi: 10.1001/archinte.164.20.2206 (2004).
12 Bauer, C.M.T., Morissette, M.C., Stämpfli, M.R. The influence of cigarette smoking on viral infections: translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically. Chest 143, 196-206. doi: 10.1378/chest.12-0930 (2013).
13 Kronbichler, A., Effenberger, M., Eisenhut, M., Lee, K.H., Shin, J.I. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: an immunological point of view. Autoimmun Rev. 19, 102570. doi: 10.1016/j.autrev.2020.102570 (2020).
14 Shi, H. et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 20, 425-434. doi: 10.1016/S1473-3099(20)30086-4 (2020).
15 Iwabuchi, K. et al. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: report of three cases. J Infect Chemother. 26, 625-632. doi: 10.1016/j.jiac.2020.04.007 (2020).
16 Russell, C.D., Millar, J.E., Baillie, J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 395, 473-475. doi: 10.1016/S0140 6736(20)30317-2 (2020).
17 RECOVERY Collaborative Group, Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19-preliminary report. N Engl J Med. 384, 693-704. doi10.1056/NEJMoa2021436 (2021).
18 Matsuyama, S. et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. J Virol. 95, e01648 20. doi: 10.1128/JVI.01648-20 (2020).
19 Alberici, F. et al. Management of patients on dialysis and with kidney transplant during SARS-COV-2 (COVID-19) pandemic In Brescia, Italy. Kidney Int Rep. 5, 580-5 (2020).